Diversified Revenue ModelHCT monetizes finished products, ingredient supply, contract manufacturing and licensing. Multiple revenue pathways reduce single-channel/customer concentration, allow monetization of IP and offer durable options to scale and shift toward higher-margin licensing or B2B ingredient sales over months.
Balance Sheet Improvement (equity Positive)Equity turning positive (~1.12M in 2025) restores a basic capital buffer after prior deficits. That improvement reduces immediate insolvency risk, can improve creditor and partner confidence, and provides a firmer platform for securing financing or support while rebuilding operations.
Gross Margin RecoveryA rise in gross margin to 13.4% from 1.6% suggests better pricing, product mix or cost control. Sustained margin improvement would materially improve earnings quality, reduce cash burn and make profitability achievable with modest revenue recovery, supporting longer-term financial stability.